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Abstract
Background: Monthly heartworm preventives are designed to protect dogs by killing heartworms acquired the
month prior to their administration, and after treatment with most products, the drug levels rapidly dissipate to
very low levels. Work with Advantage Multi® for Dogs (imidacloprid + moxidectin) topical solution showed
protection against hookworm infection throughout the month after administration of several monthly doses
suggesting that similar protection might occur with heartworms. This study assessed the amount of protection
afforded to dogs by the administration of four monthly doses of Advantage Multi for Dogs prior to infection with
third-stage heartworm larvae (Dirofilaria immitis) 28 days after the last (fourth) treatment.
Methods: There were 16 purpose-bred mongrel dogs in the study that were divided into two groups, 8 control
and 8 treated dogs. Dogs were housed in a manner preventing contact between animals and groups, and personal
protective gear worn by staff minimised the chance spread of the topically applied product between runs. The
dogs in the treated group received monthly applications of Advantage Multi for Dogs as per label instructions on
Study Days 0, 28, 56, and 84. On Study Day 112, all 16 dogs received 50 third-stage larvae of D. immitis (“Missouri”
isolate) via subcutaneous inoculation in the inguinal region. The study was terminated on Day 264, and the number
of heartworms per dog was determined at necropsy.
Results: Moxidectin levels after 4 treatments 28 days apart were near steady state on Study Day 112 when the
dogs were inoculated with D. immitis third-stage larvae. At necropsy, 152 days after infection, all the control dogs
had adult worms in their pulmonary arteries (geometric mean = 33.9; range 25–41), and none of the dogs treated
four times prior to infection, with the last treatment 30 days prior to infection, harbored worms at necropsy.
Conclusions: The efficacy of prevention was 100 % when the dogs were infected 28 days after the last monthly
treatment. When dogs receive consecutive doses of Advantage Multi for Dogs as prescribed, heartworm infections
will be prevented throughout the monthly dosing interval after administration of several monthly doses.
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Background
Prevention of heartworm disease by monthly application
of macrocyclic lactones (e.g., ivermectin, milbemycin,
moxidectin) is based on their ability to kill young devel-
oping stages (third-stage and fourth-stage larvae) that
have been acquired and begun their development during
the month prior to treatment. Treatment early in the in-
fection is required because older fourth-stage larvae and
young and older adult worms are less susceptible to the
doses that are effective against the stages that have been
in the dog less than a month [1]. Pharmacokinetic stud-
ies have shown that following the oral administration of
ivermectin and other products that there is a rapid clear-
ance of these products from the serum [2, 3]. As a con-
sequence, development of larval stages following any
new infection during the month after administration is
generally considered to progress normally until the next
monthly treatment kills any worms newly acquired in
the past month.
Advantage Multi® for Dogs (imidacloprid and moxi-
dectin) is formulated for topical administration to pro-
vide at least 10 mg/kg imidacloprid and 2.5 mg/kg
moxidectin. The moxidectin, which is the portion of the
product with activity against the internal helminth para-
sites is approved to prevent heartworm disease by killing
stages of D. immitis that are less than thirty days of age
in the dog. This product is also labelled as efficacious in
the treatment of fourth-stage larvae and adults of Ancy-
lostoma caninum, Uncinaria stenocephala, and Toxocara
canis, and the adults of Toxascaris leonina and Trichuris
vulpis.
Additional work since product approval has shown
that Advantage Multi® for Dogs and Advantage Multi®
for Cats will protect pet dogs and cats against incoming
hookworms for a month after their last treatment. When
dogs were inoculated with 300 infective larvae the hook-
worm Uncinaria stenocephala 18 days after a single
treatment with Advantage Multi® for Dogs, there were
no hookworms recovered from the treated dogs 21 days
after the larvae were administered, while the non-treated
control dogs harbored both immature adult 4.6 (SD ±
3.9) and adult hookworms 8.1 (SD ±4.3) [4] Also, the
month-long protection against incoming parasites pro-
vided by Advantage Multi can be enhanced if the pet
first receives several consecutive monthly administra-
tions. In work with canine hookworms, dogs were
treated with Advantage Multi® for Dogs on days 0, 30,
60, and 90 and were then given larvae of hookworms
22 days (U. stenocephala) and 23 days (Ancylostoma
caninum) after the last treatment. Examination of the in-
testinal tracts of the treated dogs 42 days (U. stenoce-
phala) and 41 days (A. caninum) after larval inoculation
(63 days after the last treatment) revealed no U. stenoce-
phala and only one adult A. caninum in the six treated
dogs while the non-treated control dogs examined on
the same day harbored a mean of 517.8 U. stenocephala
and 41.3 A. caninum adults [5]. Using the feline hook-
worm Ancylostoma tubaeforme in a similar study design,
when cats were infected 20 days after the last of five
monthly treatments with Advantage Multi® for Cats,
there were no hookworms recovered from the treated
cats, while there was a mean of 62.5 adult worms recov-
ered from the non-treated cats [5].
Protection following the regular monthly administra-
tion of Advantage Multi has now also been reported
relative to feline infections with D. immitis [6]. Four
monthly treatments with Advantage Multi® for Cats pro-
tected cats from subsequent regular weekly infection
with D. immitis for 28 days. These treatments prevented
both the formation of a detectable antibody response
and development of pulmonary lesions by either imma-
ture stages of D. immitis or young adult heartworms.
The work here reports on the ability of Advantage
Multi® for Dogs to protect against inoculated heartworm
larvae that were administered 28 days after the last of
four consecutive monthly doses.
Methods
Animals
Sixteen purpose-bred Mongrel dogs (8 males and 8 fe-
males) purchased from a USDA approved commercial
Class A supplier were used in this study. The dogs were
acclimated to the study environment for eight days prior
to the initial treatment. Physical examinations were per-
formed by a veterinarian on Study Day −6. General
Health Observations were conducted once daily
throughout the study. On Study Day −2, the 16 dogs
were randomly assigned to one of two treatment groups;
the animals were separated by sex, ranked by ascending
body weight, and alternately assigned to treatment
groups 1 or 2. All animals were individually housed in a
manner that prevented contact between the animals and
separated by group as a precaution against spreading of
the topically applied product between animals.
Temperature ranged from 11.7 to 27.6 °C, and overhead
fluorescent lights on an automated timer provided a 12-
h light/dark cycle throughout the study. Dogs were fed
Laboratory Canine Diet (LabDiet®, St. Louis, MO) ad
libitum, and fresh water was available to all animals
throughout the study. Personnel that performed general
health observations as well as those conducting the nec-
ropsy, dissection and heartworm counts were masked to
treatment throughout the study. All procedures in this
study were reviewed and approved by the facilities Insti-
tutional Animal Care and Use Committee and housed
according to USDA Animal Welfare Regulations, Animal
Welfare Act (9 CFR 1–3).
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Treatment
The treated group of dogs received Advantage Multi® for
Dogs, per label instructions, assuring the minimum rec-
ommended dose of 2.5 mg/kg moxidectin and 10 mg/kg
imidacloprid at days 0, 28, 56 and 84.
Inoculation with heartworms
On Study Day 112, 28 days after the last Advantage
Mutli for Dogs administration, all dogs were inoculated
with 50 infective, third-stage larvae (L3) of D. immitis
(Missouri Isolate) harvested from infected mosquitoes;
this same isolate was used in the steady state trial per-
formed with heartworms in cats [6]. Infective L3 larvae
were harvested from Aedes aegypti (Liverpool strain)
into Hanks’ Balanced Salt Solution 15 days after mem-
brane feeding on heparinised blood containing approxi-
mately 3,500 microfilariae/ml. Fifty D. immitis L3 larvae
were counted into Petri dishes for each individual ani-
mal. Excess fluid was removed from the dish to ensure
that less than 1 mL of fluid remained in each dish. The
fluid containing the larvae was then drawn into a 1 mL
syringe. The contents of the syringe were injected into
the animal subcutaneously in the inguinal region. The
syringe was rinsed several times with Hank’s Balanced
Saline Solution and reinjected to ensure all larvae were
removed from the syringe. The syringe was then rinsed
into a Petri dish and examined for remaining larvae. Any
remaining larvae were injected in the animal.
Determination of Moxidectin blood levels
For serum moxidectin level determination, blood sam-
ples were collected in serum separator tubes on Study
Days −2, 10, 27, 39, 55, 66, 83, 91, 98, 105, 112, 119,
140, 168, 181, 210, 240 and 264. The samples were then
centrifuged and the serum was harvested and stored at
−80 °C. Once all samples had been collected and frozen,
serum samples were shipped on dry ice to a laboratory
(Bayer CropScience AG, Monheim, Germany) for deter-
mination of moxidectin levels using a validated method.
Samples were first deproteinised by mixing 200 μL of
serum with 800 μL of a precipitation solution and then
filtered. The precipitation solution was prepared by mix-
ing 100 mL of a solution of 0.39 g ammonium acetate in
1 L water with 1 mL of formic acid and 600 mL of
acetonitrile. The quantitative determination of moxidec-
tin in serum was performed by high performance liquid
chromatography-tandem with tandem mass spectromet-
ric detection using an AB Sciex API 4000 mass spec-
trometer (Bayer CropScience AG Method 01086/M001).
The lower limit of quantitation was 1 μg/L.
Heartworm antigen analysis
For heartworm antigen testing, blood was collected in
tubes containing EDTA on Study Days 112, 181, 210,
240 and 264. These samples were centrifuged and the
harvested plasma was stored at −80 °C. Following study
completion, samples were sent to Auburn University.
The samples were analysed using a DiroCHEK enzyme-
linked immunosorbent assay (ELISA) for the detection
of adult D. immitis antigen in the serum. To obtain
quantitative results from this analysis, the plates were
read with a Bio-Rad iMark Microplate Reader. A stand-
ard deviation of 0.005 was added to the optical density
(OD) readout for the negative control and this number
was used as a cutoff. Any OD readout above the cutoff
was interpreted as a positive result and anything below
was interpreted as a negative result.
Post-mortem examination
On Study Day 251, all animals were randomised to nec-
ropsy order, and then on Study Day 264, all dogs were
humanely euthanised, necropsied and lungs and heart
were collected. The heart and lungs were then dissected
and any heartworms found were collected and counted
(by gender and total).
Statistics for efficacy determination
Statistics were performed using SAS® 9.3 (SAS Institute
Inc., Cary, NC, USA). The total heartworm counts from
necropsy (sum of male and female worms) from two
treatment groups were analysed by Wilcoxon’s Rank
Sum test using a two-sided exact test based on the Wil-
coxon rank-sum statistic testing for treatment group ef-
fects. An alpha of 0.05 was used to conclude a statistical
significant difference.
Pharmacokinetic evaluation
The pharmacokinetic evaluation consisted of graphical
evaluation of steady state attainment and the calculation
of apparent terminal half-lives. Phoenix WinNonlin ver-
sion 6.3.0, developed by Pharsight Corporation, was used
for graphs of individual results and half-life determin-
ation, and Microsoft Excel 2010 was used for the graph-
ical evaluation of steady state attainment. Phoenix has
been validated by Pharsight and at the site of use. Time




All eight (8) Advantage Multi®-treated dogs had no
heartworms recovered at necropsy. The eight (8) non-
treated dogs had a geometric mean heartworm count of
33.9 (ranging from 25 to 41) (Table 1). A statistical sig-
nificant difference was present between the total heart-
worm counts in both groups (P = 0.00016).
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Heartworm antigen
All dogs tested negative for heartworm antigen on Study
Days 112, 181, 210, 240. All eight treated dogs remained
sero-negative for heartworm antigen throughout the
study. On Study Day 264, 5 of the 8 dogs in control
group were antigen positive (Table 1).
Pharmacokinetic analysis
A mean graph of the pharmacokinetic data shows a
characteristic “saw tooth” multiple dose profile (Fig. 1),
with increasing concentrations with successive adminis-
trations, indicating accumulation, and eventually attain-
ment of steady state. The moxidectin level is maintained
above the Cmax of the first administration for at least an
additional 28 days after the last administration as dem-
onstrated by the serum levels at day 112, i.e., the day on
which the dogs were inoculated with D. immitis third-
stage larvae. Examination of the mean trough values
(pre-administration concentrations) more clearly shows
moxidectin accumulation with attainment of steady state
(Fig. 2). The mean terminal phase half-life was deter-
mined to be 28.4 days. Based on this half-life, steady
state (nearly 94 %) should be reached in approximately
4 × 28.4 days, or ~114 days. This is consistent with the
results observed in the graph of trough values (Fig. 2).
Discussion
Treating dogs with moxidectin four times at intervals of
28 days provided protection against a challenge with 50
third-stage larvae of D. immitis 28 days after the admin-
istration of the last of the four treatments. It would ap-
pear that steady state accumulation of moxidectin
provides levels that are capable of preventing the devel-
opment of worms for a month after the last of the four
treatments. This had previously been observed to occur
in cats that were inoculated with 25 third-stage larvae of
D. immitis 7, 14, 21, and 28 days after the last of four
monthly treatments [6]. Therefore, unlike the adminis-
tration of oral ivermectin at preventive heartworm doses
where the drug level is markedly reduced within hours
of administration [2, 7], with the topical administration
of Advantage Multi for dogs, steady state is reached with
the topically applied moxidectin with accumulation of
moxidectin that provides at least a month of protection
after the last administration to dogs that have received
four or more monthly applications. The authors also
presume based on the observed pharmacokinetic profile
that the same protection would occur after one monthly
dose due to the high serum concentration seen in the
dogs in this trial.
Besides comparison with the first low-dose macrocyc-
lic lactone used for heartworm prevention, ivermectin in
HEARTGARD®-30, topically applied Advantage Multi®
for Dogs appears unique when compared to the other
heartworm preventives in its ability to accumulate at
steady state, achieve, and maintain effective drug levels
in the body even after 28 days since the last administra-
tion. The daily oral administration of the mixture of mil-
bemycin A3A4 5-oxime (Interceptor® Flavor Tabs® for
Dogs and Cats) when given to dogs for a month and a
half falls rapidly to near zero within two weeks after the
last treatment [3], indicating that this formulation does
not accumulate and reach effective levels at steady state
as does topically applied moxidectin. The addition of
spinosad to milbemycin oxime within Trifexis®, does in-
crease the plasma levels of milbemycin oxime in treated
dogs, but even after three monthly treatments, the levels
are reduced by three orders of magnitude within 25 days
[8]. Also, it appears that accumulation is not sufficient
to create effective levels of selamectin when applied as
Revolution. Topically and orally dosed selamectin levels
fall much slower in dogs following a single application
Table 1 Worm recoveries from dogs treated with 4 monthly
doses of Advantage Multi for Dogs with the last treatment
being 28 days before being inoculated with L3 Dirofilaria
immitis larvae from mosquitoes. Shown in the table are the
dogs’ IDs and gender, ELISA OD value on Day 264 (152 days
after inoculation with larvae), and the number of male, female,
and total worms recovered from each dog
Number of Worms Recovered
Dog ID Gender ELISA OD Day 264 Males Females Total
DOGS TREATED WITH ADVANTAGE MULTI® FOR DOGS
501 Male 0.055 0 0 0
701 Male 0.052 0 0 0
801 Male 0.054 0 0 0
601 Male 0.057 0 0 0
505 Female 0.060 0 0 0
705 Female 0.056 0 0 0
703 Female 0.054 0 0 0
704 Female 0.056 0 0 0
Geometric mean: 0.00 0.00 0.00
NONTREATED CONTROL DOGS
502 Male 0.063 12 22 34
702 Male 0.055 7 18 25
306 Male 0.080* 13 21 34
401 Male 0.055 14 17 31
504 Female 0.093* 13 24 37
506 Female 0.090* 20 21 41
503 Female 0.079* 13 23 36
602 Female 0.090* 21 15 36
Geometric mean: 13.47 19.90 33.94
*The asterisk next to the OD (Optical Density) indicates these dogs were
considered antigen positive because the OD reading was >0.005 above the
negative control reading of 0.067
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Fig. 1 Levels of moxidectin in serum of dogs collected for analysis: 1. One or two days before each treatment (days −2, 27, 55, 83); 2. Ten or
eleven days following treatments one through three (days 10, 39, 66); and 3. After the last treatment (days 91, 98, 105, 112, 119, 140, 168, 181,
210, 240, and 264). Subjects were infected with heartworms on day 112
Fig. 2 Mean trough levels of moxidectin (μg/L) prior to infection with Dirofilaria immitis on Day 112. Dogs were treated with moxidectin on
Study Days 0, 28, 56, and 84 and inoculated with third-stage larvae of Dirofilaria immitis on Study Day 112
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than after intravenous administration; however, the
levels fall much more rapidly than for topically applied
moxidectin [9]. With the sustained release formulation
of moxidectin, Proheart® 6, as stated in NADA 141–189
ProHeart® 6 (moxidectin) Sustained Release Injectable
for Dogs: “Following injection with the 1X dose of Pro-
Heart 6, peak moxidectin blood levels were observed ap-
proximately 7–14 days after treatment. By Day 112 after
the first treatment, moxidectin serum levels were below
the limit of quantification (0.5 ppb) in 10 of the 12
treated dogs. Measurements taken prior to the fifth and
sixth injections showed consistently low moxidectin
serum levels. Accordingly, little or no drug accumulation
occurred with repeated administrations.” [10]. Again, it
appears that topical moxidectin is unique in its bio-
accumulation of preventive levels of anti-filarial activity
by the simple monthly topical application of the
product.
Recently, it has become apparent that there are iso-
lates of heartworms that are not killed by the single
doses of preventive products as they once were ([11–17],
McCall et al., 2013, unpublished “late breaking” poster,
14th Triennial Symposium of the American Heartworm
Society, Sept 8–10, New Orleans, LA, USA). However,
some of the products have been found to have increased
efficacy against inoculated larvae when administered
monthly for several months after infection, e.g., Trifexis®
and Sentinel® Spectrum® Chewables® (NADA 141–333)
[16, 18]. It is unclear why these repeated treatments are
efficacious, because the results of the original approvals
for HeartGard-30 (NADA 138–412) and Interceptor®
(NADA 140–915) showed that heartworms became
more refractory to macrocyclic lactone effects as they
aged [1, 19]. It now appears that perhaps the repeated
insult to developing worms from successive treatments
may prevent their development as they are repeatedly
treated after being introduced into dogs. The susceptibil-
ity of these developing forms to repeated dosages of
macrocyclic lactone suggests that the constant high
levels of moxidectin in the blood of dogs on regular
monthly Advantage Multi® for Dogs may increase the
chance of it killing these incoming worms that are no
longer killed by the single dose of low-dose macrocyclic
lactone. If one examines the curve of the mean pharma-
cokinetic results (Fig. 2), it can be seen that the treat-
ment levels with Advantage Multi® for Dogs are actually
higher after 2 or 3 applications than after a single appli-
cation, and topical moxidectin has had excellent activity
against less susceptible heartworm isolates with only a
single application (McCall et al., 2013, unpublished “late
breaking” poster, 14th Triennial Symposium of the
American Heartworm Society, Sept 8–10, New Orleans,
LA, USA) ([11, 12], McCall et al., 2013, unpublished
“late breaking” poster, 14th Triennial Symposium of the
American Heartworm Society, Sept 8–10, New Orleans,
LA, USA). Thus, as topically applied Advantage Multi®
for Dogs reaches steady state after several applications, it
may be that when the high level of moxidectin is avail-
able it will kill all new infections of susceptible isolates.
This may even be efficacious against the less susceptible
isolates that require several consecutive monthly treat-
ments for prevention to occur. This is something that
might be worthy of testing experimentally. At this point
in time, it can be speculated that the continued year-
round application of monthly topical moxidectin in the
form of Advantage Multi® for Dogs may be a means of
protecting dogs against these new resistant isolates of D.
immitis.
Conclusions
The administration of several monthly applications of
moxidectin in topically applied Advantage Muti® for
Dogs provides levels of moxidectin that are protective
against incoming third-stage larvae of D. immitis for at
least a month after the last dose is administered. The
pharmacokinetic profile suggests that this may even be
the case after only a single dose of topical moxidectin as
formulated in Advantage Multi® for Dogs.
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